GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Impax Laboratories, Inc. (IPXL) [hlAlert]

Rating:
Buy IPXL
up 75.73 %

Impax Laboratories, Inc. (IPXL) rated Buy with price target $30 by Auriga

Posted on: Tuesday,  Apr 17, 2012  3:25 PM ET by Auriga

Auriga rated Buy Impax Laboratories, Inc. (NASDAQ: IPXL) on 04/17/2012, when the stock price was $25.02. Since
then, Impax Laboratories, Inc. has gained 75.74% as of 01/20/2016's recent price of $43.97.
If you would have followed this Auriga's recommendation on IPXL, you would have gained 75.73% of your investment in 1373 days.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

Auriga operates full-service institutional equity and fixed income trading desks with state-of-the-art communications technology and trading systems. Through our U.S. corprate parent, Auriga Holdings, LLC we offer a variety of services including whole loan trading and asset management. Through our Spanish parent company, Auriga Securities Sociedad de Valores, S.A., we offer the ability to trade European equity and fixed income products. We connect electronically to buy-side firms; route orders to multiple points of execution and subsequently route to our clearing firm, Pershing, for settlement.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/17/2012 3:25 PM Buy
None
25.02 30.00
as of 12/31/2012
1 Week up  0.44 %
1 Month up  0.73 %
3 Months down  -21.07 %
1 YTD down  -18.10 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy